
Sign up to save your podcasts
Or


We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.
By Retina Synthesis4.5
88 ratings
We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

43 Listeners

18 Listeners

100 Listeners

113,475 Listeners

56,978 Listeners

5 Listeners

9,559 Listeners

12 Listeners

47,440 Listeners

50 Listeners

12 Listeners

471 Listeners

19 Listeners

0 Listeners